agilon health, inc. (AGL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-27

Key Insights

Tim O'Rourke appointed as new CEO and President with 25+ years of healthcare industry experience, including senior roles at Humana, Centene, and Ascension, suggesting strategic leadership continuity in the managed care sector.
Aggressive performance-based compensation structure includes PSUs vesting at stock price targets of $50, $100, and $150, aligning leadership incentives with significant shareholder value creation over the three-year period.
Total first-year compensation package of approximately $1.85 million base and signing bonus plus equity grants demonstrates board confidence in turnaround strategy, though substantial equity dilution from 320,000 RSU/PSU grant.
Change-of-control severance provisions (18 months base + target bonus, plus accelerated vesting) and robust RSU acceleration clauses provide executive downside protection typical of CEO-level agreements in healthcare sector.

Want the newest filings?

This analysis covers the filing from 2026-04-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-18

agilon health, Inc. (AGL) has approved a reverse stock split of its common stock at a ratio of 1-for-25, which is intended to increase the stock price and potentially improve the company's trading liquidity.
The reverse split was approved by shareholders at a special meeting, indicating strong support for the corporate action among investors.
The reverse split is expected to be implemented on March 30, 2026, which could provide an opportunity for investors to reevaluate their positions in the company.

Filed: 2026-01-07

agilon health, Inc. (AGL) has entered into an Amended and Restated Employment Agreement with its Chief Financial Officer and Executive Vice President, Jeffrey Schwaneke, effective January 1, 2026.
The Amended Employment Agreement provides for a one-time equity award of 600,000 restricted stock units (RSUs) to Mr. Schwaneke, as well as eligibility for annual equity awards in fiscal years 2026 and 2027.
The agreement also outlines severance and equity vesting provisions in the event of Mr. Schwaneke's termination by the company without cause or his voluntary termination after 18 months.

Other reports for agilon health, inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.